40 completed, 6 recruiting, 4 unknown, 2 not yet recruiting. 55 Phase 2, 6 Phase 3, 5 Phase 1.
Follow Central Nervous System Bacterial Infections: new trials by email Literature Review of Central Nervous System Bacterial Infections trials Research Report on Central Nervous System Bacterial Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BPaLMZ for TB Meningitis BPaLMZ Regimen - Tuberculous Meningitis, HIV | Phase 2 | Recruiting | David Boulware | 312 | 2026-07-28 | 2026-10-16 |
| Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients VM100 Nutritional Supplement - Duchenne Muscular Dystrophy, Duchenne Disease | Phase 2 | Recruiting | University of Florida | 20 | 2026-07-27 | 2026-10-08 |
| Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex BV100 with 50 mg polymyxin B plus ceftazidime/avibactam, BV100 with 50 mg polymyxin B plus cefiderocol, Best Available Therapy (BAT) - Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP) | Phase 2 | Not yet recruiting | BioVersys AG | 120 | 2026-07-01 | 2026-02-24 |
| Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis HRZE, HRZE plus Alpe375, HRZE plus AlpE500 - Tuberculosis Meningitis | Phase 2 | Not yet recruiting | BioVersys AG | 64 | 2026-03-30 | 2026-03-03 |
| Adjunctive Doxycycline for Central Nervous System Tuberculosis Doxycycline, Placebo, Anti Tuberculosis Drug - Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology) | Phase 2 | Recruiting | National University Hospital, Singapore | 200 | 2025-08-21 | 2026-06-01 |
| Vasodilator and Exercise Study for DMD (VASO-REx) Tadalafil, Placebo, Exercise Training - Duchenne Muscular Dystrophy, Duchenne Disease | Phase 2 | Recruiting | University of Florida | 50 | 2024-06-05 | 2026-05-15 |
| A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine ACYW135 Meningococcal Polysaccharide Conjugate Vaccine, ACYW135 Meningococcal Polysaccharide Vaccine - Meningococcal Meningitis | Phase 2 | Unknown | Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | 1200 | 2024-03-20 | 2024-03-29 |
| Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis Contezolid, Linezolid (LZD) - Tuberculosis, Meningitis | Phase 1 / Phase 2 | Enrolling by invitation | Beijing Chest Hospital | 24 | 2024-02-01 | 2025-02-06 |
| Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD) - Tuberculous Meningitis | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 330 | 2023-12-07 | 2026-06-02 |
| Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis Adalimumab Injection - Tuberculous Meningitis, HIV I Infection | Phase 2 | Recruiting | ANRS, Emerging Infectious Diseases | 130 | 2023-04-11 | 2025-12-15 |
| Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents MenABCWY vaccine, Placebo - Meningitis, Meningococcal | Phase 2 | Active not recruiting | GlaxoSmithKline | 305 | 2021-11-18 | 2026-09-28 |
| Pharmacokinetic Study of Linezolid for TB Meningitis Linezolid - Tuberculosis, Meningeal, Linezolid | Phase 2 | Completed | Universitas Padjadjaran | 36 | 2021-06-21 | 2023-09-06 |
| Adjunctive Linezolid for the Treatment of Tuberculous Meningitis LZD, High dose RIF, Standard dose RIF - Tuberculosis, Meningeal | Phase 2 | Completed | University of California, San Francisco | 40 | 2021-05-05 | 2024-10-01 |
| Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis Cyclophosphamide injection - Tuberculosis, Tubercular Meningitis | Phase 2 / Phase 3 | Unknown | All India Institute of Medical Sciences | 40 | 2021-01-01 | 2020-12-30 |
| Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM Linezolid, High dose rifampicin, Aspirin - Tuberculosis Meningitis, HIV-1-infection | Phase 2 | Completed | University of Cape Town | 52 | 2019-06-12 | 2021-09-28 |
| Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months Meningococcal ACYW135 Polysaccharide Conjugate Vaccine - Meningitis, Meningococcal | Phase 2 | Completed | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 720 | 2018-12-21 | 2022-02-25 |
| Conjugate Vaccine Against Meningococcus C a Brazilian Project MenCC-BIO Vaccine, Combined - CRM197 - Serogroup C Meningococcal Meningitis | Phase 2 / Phase 3 | Unknown | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 1644 | 2018-09-25 | 2018-10-10 |
| A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age MenACWY liquid, MenACWY - Meningitis, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 1707 | 2018-08-30 | 2021-02-17 |
| Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years MenABCWY vaccine, rMenB+OMV NZ (Bexsero) vaccine, MenACWY (Menveo) vaccine - Meningitis, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 520 | 2018-07-09 | 2020-02-12 |
| Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis Daptomycin - Pneumococcal Meningitis | Phase 2 | Completed | Centre Hospitalier Universitaire Dijon | 112 | 2018-06-07 | 2024-10-01 |
Showing 20 of 55. Sign in to see all of them.
Meningitis, Meningococcal (35) · Meningitis (20) · Meningococcal Infections (18) · Tuberculosis, Meningeal (15) · Tuberculosis (5) · Central Nervous System Infections (2) · Latent Tuberculosis (2) · Muscular Dystrophies (2) · Muscular Dystrophy, Duchenne (2) · Tabes Dorsalis (2) · Aneurysm (1) · Arachnoiditis (1) · Borrelia Infections (1) · Central Nervous System Diseases (1) · Cerebral Ventriculitis (1)
Bacterial Infections (55) · Bacterial Infections and Mycoses (55) · Infections (55) · Nervous System Diseases (55) · Central Nervous System Diseases (54) · Central Nervous System Infections (53) · Neuroinflammatory Diseases (52) · Meningitis, Bacterial (51) · Gram-Negative Bacterial Infections (38) · Neisseriaceae Infections (35) · Meningitis (32) · Gram-Positive Bacterial Infections (17) · Meningococcal Infections (17) · Actinomycetales Infections (16)
Meningococcal Vaccines (11) · Rifampin (6) · Linezolid (5) · 4CMenB vaccine (4) · Vaccines (3) · Aspirin (2) · Isoniazid (2) · MenACWY (2) · Adalimumab (1) · Antipyretics (1) · Antitubercular Agents (1) · Blood Specimen Collection (1) · Cefiderocol (1) · Ceftazidime (1) · Ceftriaxone (1)
Novartis Vaccines (9) · Sanofi Pasteur, a Sanofi Company (5) · GlaxoSmithKline (4) · Universitas Padjadjaran (4) · Pfizer (3) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (2) · BioVersys AG (2) · Sanofi (2) · University of Florida (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · ANRS, Emerging Infectious Diseases (1) · Aimei Vacin BioPharm (Zhejiang) Co., Ltd. (1) · All India Institute of Medical Sciences (1) · Armauer Hansen Research Institute, Ethiopia (1) · Beijing Chest Hospital (1)
United States (14) · Indonesia (5) · Brazil (4) · Chile (4) · China (4) · Spain (4) · Czechia (3) · Finland (3) · Poland (3) · South Africa (3) · United Kingdom (3) · Vietnam (3) · Australia (2) · Colombia (2) · France (2)
Rovina Ruslami, M.D., PhD (2) · Abraham Aseffa Aseffa, M.D, PhD (1) · Ahmad R Ganiem, MD, PhD (1) · Ahmed Bedru Omer, M.D,Pediatrician (1) · Alberto Yataco, MD (1) · Angharad G Davis, Dr (1) · Brian Fallon, M.D. (1) · David Boulware, MD (1)
PMID 35164991, PMID 17548138, PMID 21177912, PMID 22569484, PMID 23103177, PMID 23114372, PMID 23352429, PMID 25077420, PMID 25424810, PMID 25703312, PMID 25969894, PMID 26075813, PMID 26135245, PMID 26756390, PMID 27745812, PMID 29482717, PMID 30224533, PMID 32209248, PMID 32233959, PMID 32233961, PMID 32681472, PMID 33020485, PMID 33767093, PMID 33972248, PMID 34077644, PMID 34286103, PMID 34787449, PMID 35257644, PMID 35291004, PMID 36369456, PMID 36482216, PMID 37491088, PMID 37740554, PMID 40043411
2008 (2), 2009 (2), 2017 (2), 2014 (1), R01HD074944 (1), R21AR079755 (1), R21TW011035 (1)